




		EMLc	ATC codes: J05AG01
Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified	ICD11 code: <a href="#">1C62.Z</a>	
INN	Nevirapine		
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Formulations	Oral > Liquid: 50 mg per 5 mL Oral > Solid > dispersible tablet: 50 mg Oral > Solid > tablet: 200 mg (EML)		
EML status history	First added in 1999 ( <a href="#">TRS 895</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Age restriction	> 6 weeks		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Nevirapine</a> 		
DrugBank	<a href="#">Nevirapine</a> 		

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an “optimal” paediatric formulation.

